BDBM433449 US10562850, Compound 42l::US10562850, Compound 43m::US11066360, Compound 42l::US11066360, Compound 43m

SMILES CO[C@@H]1C[C@@H](N(C1)C(=O)Nc1ccc(Cl)cn1)C(=O)Nc1cc(ccc1F)C(CCC1CC1)n1ccccc1=O

InChI Key InChIKey=XUORFTPJFLKHSK-UHFFFAOYSA-N

Data  4 KI

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 4 hits for monomerid = 433449   

TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM433449(US10562850, Compound 42l | US10562850, Compound 43...)
Affinity DataKi: <50nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2020
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM433449(US10562850, Compound 42l | US10562850, Compound 43...)
Affinity DataKi: <50nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/19/2021
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM433449(US10562850, Compound 42l | US10562850, Compound 43...)
Affinity DataKi:  75nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2020
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM433449(US10562850, Compound 42l | US10562850, Compound 43...)
Affinity DataKi:  75nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/19/2021
Entry Details
Go to US Patent